GeNeuro, Servier 'Disappointed' With Mid-Way Phase IIb Multiple Sclerosis Study
Executive Summary
GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.
You may also be interested in...
Partnerships Picks For GeNeuro’s MS Antibody
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.
GeNeuro Homes In On Ancestral Viral Genes To Treat Autoimmune Diseases
Focusing on an idea that many autoimmune diseases are caused by proteins from viral genes that are now embedded in human DNA, Swiss biotech GeNeuro is using the idea to develop therapeutics.